Publications

Scientific publications showcasing our QSP modeling, translational research, and clinical trial design.

Publications

Scientific publications showcasing our QSP modeling, translational research, and clinical trial design.

Publications

Scientific publications showcasing our QSP modeling, translational research, and clinical trial design.

MODALITY

2025

Quantitative Systems Pharmacology Modeling of Platelet Responses to Recombinant ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura

Rare diseases – congenital thrombotic thrombocytopenic purpura (cTTP)

Monoclonal antibody

2025

Quantitative Systems Pharmacology Modeling of Platelet Responses to Recombinant ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura

Rare diseases – congenital thrombotic thrombocytopenic purpura (cTTP)

Monoclonal antibody

2024

A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema

HAE

Monoclonal antibody

2024

A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema

HAE

Monoclonal antibody

2024

Quantitative Systems Pharmacology Modeling of Adeno-Associated Virus Gene Therapies: Mechanistic Identification of Species-Translation Using Preclinical and Clinical Data (Chapter 4 in Development of Gene Therapies, eds. Avery McIntosh, Oleksandr Sverdlov)

Rare diseases - hemophelia B

Gene therapy

2024

Quantitative Systems Pharmacology Modeling of Adeno-Associated Virus Gene Therapies: Mechanistic Identification of Species-Translation Using Preclinical and Clinical Data (Chapter 4 in Development of Gene Therapies, eds. Avery McIntosh, Oleksandr Sverdlov)

Rare diseases - hemophelia B

Gene therapy

2024

In vitro evaluation of myelosuppressive effects of ATRi tuvusertib and ATMi lartesertib (M4076), alone and in combination.

Cancer - various

Small molecule

2024

In vitro evaluation of myelosuppressive effects of ATRi tuvusertib and ATMi lartesertib (M4076), alone and in combination.

Cancer - various

Small molecule

2024

Achieving Uniform Vector Genome Transduction in the Brain Tissue after Intraparenchymal Delivery of Adeno Associated Virus Gene Therapy Using Computational Fluid Dynamics and Quantitative Systems Pharmacology Modeling

Neuorlogical - Huntington's disease

Gene therapy

2024

Achieving Uniform Vector Genome Transduction in the Brain Tissue after Intraparenchymal Delivery of Adeno Associated Virus Gene Therapy Using Computational Fluid Dynamics and Quantitative Systems Pharmacology Modeling

Neuorlogical - Huntington's disease

Gene therapy

2022

Translational PK/PD/efficacy modeling and efficacious human dose prediction for a first-in-class MUC1-EGFR (M1231) bispecific antibody drug conjugate

Cancer - various

Antibody Drug Conjugate

2022

Translational PK/PD/efficacy modeling and efficacious human dose prediction for a first-in-class MUC1-EGFR (M1231) bispecific antibody drug conjugate

Cancer - various

Antibody Drug Conjugate

2022

Developing a robust Quantitative Systems Pharmacology model of adeno-associated virus (AAV) based gene therapy for clinical applications

Rare diseases - hemophelia B

Cell therapy (Engineered B-cell)

2022

Developing a robust Quantitative Systems Pharmacology model of adeno-associated virus (AAV) based gene therapy for clinical applications

Rare diseases - hemophelia B

Cell therapy (Engineered B-cell)

2020

A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics

Various

Monoclonal antibody

2020

A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics

Various

Monoclonal antibody

2020

Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1

Cancer

Antibody Drug Conjugate

2020

Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1

Cancer

Antibody Drug Conjugate

2020

A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat

Lysosomal diseases - Gaucher

Monoclonal antibody

2020

A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat

Lysosomal diseases - Gaucher

Monoclonal antibody

2020

Quantitative Systems Pharmacology Dissection of IL-4/IL-13 Contribution to Human Allergic IgE Production (page 180)

Allergic diseases such as asthma

Monoclonal antibody

2020

Quantitative Systems Pharmacology Dissection of IL-4/IL-13 Contribution to Human Allergic IgE Production (page 180)

Allergic diseases such as asthma

Monoclonal antibody

2020

Development of a QSP model for ADAMTS13 and von Willebrand factor interactions (page 33)

Rare diseases - thrombotic thrombocytopenic purpura (TTP)

Monoclonal antibody

2020

Development of a QSP model for ADAMTS13 and von Willebrand factor interactions (page 33)

Rare diseases - thrombotic thrombocytopenic purpura (TTP)

Monoclonal antibody

2020

Hereditary angioedema (HAE) prophylaxis with plasma kallikrein inhibitors: Role of target binding kinetics, pharmacokinetics and treatment adherence (page 277)

Rare diseases - hereditary angioedema (HAE)

Monoclonal antibody

2020

Hereditary angioedema (HAE) prophylaxis with plasma kallikrein inhibitors: Role of target binding kinetics, pharmacokinetics and treatment adherence (page 277)

Rare diseases - hereditary angioedema (HAE)

Monoclonal antibody

2019

A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data

Various

Monoclonal antibody

2019

A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data

Various

Monoclonal antibody

2019

Integrated efficacy-safety QSP model of acute myeloid leukemia (AML) generates insights into the role of clinical dose schedules on cytopenia

Oncology - acute myeloid leukemia (AML)

Antibody Drug Conjugate

2019

Integrated efficacy-safety QSP model of acute myeloid leukemia (AML) generates insights into the role of clinical dose schedules on cytopenia

Oncology - acute myeloid leukemia (AML)

Antibody Drug Conjugate

2019

A mechanism-based translational mathematical model for gastrointestinal toxicity

Oncology - gastrointestinal toxicity

Small molecule

2019

A mechanism-based translational mathematical model for gastrointestinal toxicity

Oncology - gastrointestinal toxicity

Small molecule

2018

Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules

Cancer - gastrointestinal (GI) adverse events (AEs)

Small molecule

2018

Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules

Cancer - gastrointestinal (GI) adverse events (AEs)

Small molecule

2018

Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology

Lysosomal diseases - acid sphingomyelinase deficiency (ASMD)

Monoclonal antibody

2018

Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology

Lysosomal diseases - acid sphingomyelinase deficiency (ASMD)

Monoclonal antibody

2016

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

Oncology - B cell malignancies including non-Hodgkin's lymphoma (NHL) and acute lymphocytic leukemia (ALL)

Antibody Drug Conjugate

2016

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

Oncology - B cell malignancies including non-Hodgkin's lymphoma (NHL) and acute lymphocytic leukemia (ALL)

Antibody Drug Conjugate

2015

Dose and schedule predictions for the ATR inhibitor AZD6738

Oncology - many diseases, including ataxia telangiectasia (AT), chronic lymphocytic leukemia (CLL) and colorectal cancer (CRC)

Small molecule

2015

Dose and schedule predictions for the ATR inhibitor AZD6738

Oncology - many diseases, including ataxia telangiectasia (AT), chronic lymphocytic leukemia (CLL) and colorectal cancer (CRC)

Small molecule

2015

Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies

Virology - hepatits C virus (HCV)

Small molecule

2015

Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies

Virology - hepatits C virus (HCV)

Small molecule

2015

Optimization of an Aminothiazine Ring Formation: Integrating Modeling with Experiments to Maximize Yield by Minimizing Impurity Formation

Various

Small molecule

2015

Optimization of an Aminothiazine Ring Formation: Integrating Modeling with Experiments to Maximize Yield by Minimizing Impurity Formation

Various

Small molecule

2014

Modeling Tablet Dissolution in Complex Hydrodynamic Environments

Various

Small molecule

2014

Modeling Tablet Dissolution in Complex Hydrodynamic Environments

Various

Small molecule

2014

Modeling Population Heterogeneity in Viral Dynamics for Chronic Hepatitis C Infection: Insights from Phase 3 Telaprevir Clinical Studies

Virology - hepatits C virus (HCV)

Small molecule

2014

Modeling Population Heterogeneity in Viral Dynamics for Chronic Hepatitis C Infection: Insights from Phase 3 Telaprevir Clinical Studies

Virology - hepatits C virus (HCV)

Small molecule

2014

A Theoretical Approach to Modeling Renal Pharmacokinetics

Various

Small molecule

2014

A Theoretical Approach to Modeling Renal Pharmacokinetics

Various

Small molecule

2012

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection

Virology - hepatits C virus (HCV)

Small molecule

2012

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection

Virology - hepatits C virus (HCV)

Small molecule

2011

Comprehensive mechanism-based antibody pharmacokinetic modeling

Various

Monoclonal antibody

2011

Comprehensive mechanism-based antibody pharmacokinetic modeling

Various

Monoclonal antibody

2010

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

Virology - hepatits C virus (HCV)

Small molecule

2010

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

Virology - hepatits C virus (HCV)

Small molecule

2010

Modeling, Optimization, and Applications of Kinetic Mechanisms with OpenChem

Various

Small molecule

2010

Modeling, Optimization, and Applications of Kinetic Mechanisms with OpenChem

Various

Small molecule

2009

Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data

Cancer - various

Monoclonal antibody

2009

Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data

Cancer - various

Monoclonal antibody